Clinical trial
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
NCT00101335 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00101335 |
|---|---|
| Title | Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia |
| Official title | A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Precancerous Condition |
| Intervention type | Drug |
| Interventions | celecoxib |
| Start date | Nov 1, 2003 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jan 10, 2005 |
| Last update posted | Jul 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: